Health and Healthcare

Thursday's Top Biotech and Medical Stocks

Biotechnology

SEATTLE GENETICS I [SGEN] +15.33%
GILEAD SCIENCES [GILD] +11.21%
CHELSEA THERAPEUTICS [CHTP] +11.01%
SGX PHARMACEUTICALS [SGXP] +9.41%
IDM PHARMA INC [IDMI] +9.39%

Diagnostic Substances

RG GLBL LIFESTYLS [RGBL.OB] +12.50%
SYNOVICS PHARMACEUTL [SYVC.OB] +7.14%
IMMUNOMEDICS INC [IMMU] +7.07%
GENE LOGIC INC [GLGC] +6.06%
ORCHID CELLMARK INC [ORCH] +5.31%

Drug Delivery

ELAN CP PLC ADR [ELN] +5.78%
PETMED EXPRESS INC [PETS] +4.48%
PENWEST PHARM CO [PPCO] +3.44%
FLAMEL TECH SA ADR [FLML] +3.16%
BIOVAIL CORP [BVF] +3.09%

Drug Manufacturers

NEXMED INC [NEXM] +42.26%
BRADLEY PHARMACTCL [BDY] +5.02%
SIGA TECH INC [SIGA] +3.73%
ISIS PHARM INC [ISIS] +3.66%
COLLAGENEX PHARM I [CGPI] +3.60%

Medical Appliances & Equipment

CUTERA, INC. [CUTR] +16.63%
SONIC INNOVATIONS [SNCI] +15.73%
TRIMEDYNE INC [TMED.OB] +8.57%
NORTH AMERN SCI [NASI] +7.69%
CELSION CORP [CLN] +5.80%

Medical Instruments & Supplies

ROCHESTER MEDICAL [ROCM] +9.52%
YOUNG INNOVATIONS [YDNT] +5.51%
FOXHOLLOW TECH INC [FOXH] +4.19%
NUCRYST PHARMACEUTIC [NCST] +3.81%
IVAX DIAGNOSTICS INC [IVD] +3.45%

Medical Laboratories & Research

ERESEARCHTECHNOLOG [ERES] +5.00%
GENOMIC HEALTH, INC. [GHDX] +3.46%
BIO-REFERENCE LAB [BRLI] +3.27%
ENZO BIOCHEM INC [ENZ] +1.68%
PREMD INC [PME] +1.31%

http://www.biohealthinvestor.com/

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.